128 related articles for article (PubMed ID: 30443295)
41. Correction: Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells.
Tsai CH; Tsai HC; Huang HN; Hung CH; Hsu CJ; Fong YC; Hsu HC; Huang YL; Tang CH
Oncotarget; 2018 Oct; 9(85):35598. PubMed ID: 30473753
[TBL] [Abstract][Full Text] [Related]
42. Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
Oncotarget; 2018 Jul; 9(54):30472. PubMed ID: 30101001
[TBL] [Abstract][Full Text] [Related]
43. Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Khatri A; Gu JJ; McKernan CM; Xu X; Pendergast AM
Oncotarget; 2019 Oct; 10(57):6045-6046. PubMed ID: 31666936
[TBL] [Abstract][Full Text] [Related]
44. Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.
Hu Y; Yu T; Liu X; He Y; Deng L; Guo J; Hua Y; Luo T; Gao X
Oncotarget; 2020 Sep; 11(37):3484-3485. PubMed ID: 32973972
[TBL] [Abstract][Full Text] [Related]
45. Correction: New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status.
Telechea-Fernández M; Rodríguez-Fernández L; García C; Zaragozá R; Viña JR; Cervantes A; García-Trevijano ER
Oncotarget; 2018 Apr; 9(26):18664. PubMed ID: 29722369
[TBL] [Abstract][Full Text] [Related]
46. Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
Evans JP; Winiarski BK; Sutton PA; Jones RP; Ressel L; Duckworth CA; Pritchard DM; Lin ZX; Fretwell VL; Tweedle EM; Costello E; Goldring CE; Copple IM; Park BK; Palmer DH; Kitteringham NR
Oncotarget; 2019 Jan; 10(6):685. PubMed ID: 30774766
[TBL] [Abstract][Full Text] [Related]
47. Correction: P-cadherin mutations are associated with high basal Wnt activity and stemness in canine mammary tumor cell lines.
Timmermans-Sprang E; Collin RWJ; Henkes A; Philipsen M; Mol JA
Oncotarget; 2020 Feb; 11(5):573. PubMed ID: 32082491
[TBL] [Abstract][Full Text] [Related]
48. Correction: Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models.
Feldman T; Grossman-Haham I; Elkis Y; Vilela P; Moskovits N; Barshack I; Salame TM; Fass D; Ilani T
Oncotarget; 2020 Oct; 11(40):3687. PubMed ID: 33088428
[TBL] [Abstract][Full Text] [Related]
49. Correction: A new bioluminescent reporter system to study the biodistribution of systematically injected tumor-derived bioluminescent extracellular vesicles in mice.
Gangadaran P; Li XJ; Lee HW; Oh JM; Kalimuthu S; Rajendran RL; Son SH; Baek SH; Singh TD; Zhu L; Jeong SY; Lee SW; Lee J; Ahn BC
Oncotarget; 2020 Mar; 11(11):1004-1005. PubMed ID: 32215188
[TBL] [Abstract][Full Text] [Related]
50. Correction: Gene function analysis and underlying mechanism of esophagus cancer based on microarray gene expression profiling.
Yue Y; Song M; Qiao Y; Li P; Yuan Y; Lian J; Wang S; Zhang Y
Oncotarget; 2020 Mar; 11(9):891-892. PubMed ID: 32180901
[TBL] [Abstract][Full Text] [Related]
51. Correction: Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival.
Maimouni S; Lee MH; Sung YM; Hall M; Roy A; Ouaari C; Hwang YS; Spivak J; Glasgow E; Swift M; Patel J; Cheema A; Kumar D; Byers S
Oncotarget; 2021 Oct; 12(22):2305-2306. PubMed ID: 34733422
[TBL] [Abstract][Full Text] [Related]
52. Correction: The role of substance P in epilepsy and seizure disorders.
Wang XF; Ge TT; Fan J; Yang W; Li B; Cui RJ
Oncotarget; 2019 May; 10(37):3576. PubMed ID: 31191827
[TBL] [Abstract][Full Text] [Related]
53. Correction: PPARγ sumoylation-mediated lipid accumulation in lung cancer.
Phan ANH; Vo VTA; Hua TNM; Kim MK; Jo SY; Choi JW; Kim HW; Son J; Suh YA; Jeong Y
Oncotarget; 2019 Feb; 10(14):1473. PubMed ID: 30858930
[TBL] [Abstract][Full Text] [Related]
54. Correction: Incidence and risk of regorafenib-induced hepatotoxicity.
Zhao B; Zhao H
Oncotarget; 2019 Jan; 10(2):253. PubMed ID: 30719219
[TBL] [Abstract][Full Text] [Related]
55. Correction: Molecular response prediction in CML: novel ideas?
Wolf D; Sopper S
Oncotarget; 2018 Nov; 9(88):35871. PubMed ID: 30533202
[TBL] [Abstract][Full Text] [Related]
56. Correction: p53 and metabolism: from mechanism to therapeutics.
Simabuco FM; Morale MG; Pavan ICB; Morelli AP; Silva FR; Tamura RE
Oncotarget; 2018 Sep; 9(74):34030. PubMed ID: 30338044
[TBL] [Abstract][Full Text] [Related]
57. Correction: Genetically enhanced T lymphocytes and the intensive care unit.
Tat T; Li H; Constantinescu CS; Onaciu A; Chira S; Osan C; Pasca S; Petrushev B; Moisoiu V; Micu WT; Berce C; Tranca S; Dima D; Berindan-Neagoe I; Shen J; Tomuleasa C; Qian L
Oncotarget; 2018 Aug; 9(62):32097. PubMed ID: 30174800
[TBL] [Abstract][Full Text] [Related]
58. Correction: LncRNA-SVUGP2 suppresses progression of hepatocellular carcinoma.
Hu J; Song C; Duan B; Zhang X; Li D; Zhu L; Gao H
Oncotarget; 2018 Jul; 9(58):31311. PubMed ID: 30131857
[TBL] [Abstract][Full Text] [Related]
59. Correction: Beneficial bacteria inhibit cachexia.
Varian BJ; Gourishetti S; Poutahidis T; Lakritz JR; Levkovich T; Kwok C; Teliousis K; Ibrahim YM; Mirabal S; Erdman SE
Oncotarget; 2018 Jun; 9(50):29536. PubMed ID: 30034637
[TBL] [Abstract][Full Text] [Related]
60. Correction: Endonuclease G promotes mitochondrial genome cleavage and replication.
Wiehe RS; Gole B; Chatre L; Walther P; Calzia E; Palmer A; Gebhardt JCM; Ricchetti M; Wiesmüller L
Oncotarget; 2018 Jun; 9(45):27908. PubMed ID: 29963248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
